There are 2789 resources available
1081P - Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
Presenter: Jesper Breeschoten
Session: ePoster Display
1082P - Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
Presenter: Filip Janku
Session: ePoster Display
1083P - A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
Presenter: Alexander Shoushtari
Session: ePoster Display
1084P - PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
Presenter: Caroline Robert
Session: ePoster Display
1035TiP - A phase I/Ib study of MPT-0118 as monotherapy and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors
Presenter: David Sommerhalder
Session: ePoster Display
Resources:
Abstract
1042P - Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)
Presenter: Ines Pires da Silva
Session: ePoster Display
1043P - NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma
Presenter: Maysa Vilbert
Session: ePoster Display
1044P - Sequential targeted and immunotherapies in stage IV melanoma
Presenter: Teresa Amaral
Session: ePoster Display
1045P - Comparison between first-line target therapy and immunotherapy in different prognostic categories of BRAF mutant metastatic melanoma patients
Presenter: Riccardo Marconcini
Session: ePoster Display
1046P - First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)
Presenter: Yasuhiro Nakamura
Session: ePoster Display